{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:24:55Z","timestamp":1774538695024,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013965","name":"Eastern Virginia Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","award":["Medicines360"],"award-info":[{"award-number":["Medicines360"]}],"id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.contraception.2023.110136","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T20:33:06Z","timestamp":1691267586000},"page":"110136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4\u00a0mg (24\/4-day regimen) in obese users"],"prefix":"10.1016","volume":"128","author":[{"given":"Mitchell D.","family":"Creinin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicyoy","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9137-0950","authenticated-orcid":false,"given":"Enrico","family":"Colli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2023.110136_bib1","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCRESAHA.115.306885","article-title":"Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease","volume":"118","author":"Fuster","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.contraception.2023.110136_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4236\/ojpm.2012.24069","article-title":"The effects of obesity on venous thromboembolism: a review","volume":"2","author":"Yang","year":"2012","journal-title":"Open J Prev Med"},{"key":"10.1016\/j.contraception.2023.110136_bib3","unstructured":"United States Centers for Disease Control and Prevention. Adult obesity facts. \u3008https:\/\/www.cdc.gov\/obesity\/data\/adult.html\u3009 (accessed June 2022)."},{"key":"10.1016\/j.contraception.2023.110136_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002968","article-title":"The overweight and obesity transition from the wealthy to the poor in low- and middle-income countries: a survey of household data from 103 countries","volume":"16","author":"Templin","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.contraception.2023.110136_bib5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0140-6736(72)91492-4","article-title":"Randomised double-blind trial of four oral progestogen-only contraceptives","volume":"299","author":"Vessey","year":"1972","journal-title":"The Lancet"},{"key":"10.1016\/j.contraception.2023.110136_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0010-7824(82)90047-6","article-title":"A randomized, double-blind study of two combined and two progestogen-only oral contraceptives","volume":"25","author":"Sheth","year":"1982","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/13625189809167250","volume":"3","year":"1998","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2023.110136_bib8","first-page":"1","article-title":"Current contraceptive status among women aged 15\u201349: United States, 2015-2017.","volume":"388","author":"Daniels","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.contraception.2023.110136_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.contraception.2017.11.007","article-title":"Obesity and contraceptive use among women 20-44 years of age in the United States: results from the 2011-15 National Survey of Family Growth (NSFG)","volume":"97","author":"Mosher","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.contraception.2015.02.006","article-title":"Weight and body mass index among female contraceptive clients","volume":"91","author":"Kohn","year":"2015","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.contraception.2023.110136_bib11","article-title":"Hormonal contraceptives for contraception in overweight or obese women","volume":"2016","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2023.110136_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/17512433.2015.974558","article-title":"How can we improve oral contraceptive success in obese women?","volume":"8","author":"Cherala","year":"2015","journal-title":"Expert Rev Clin Pharm"},{"key":"10.1016\/j.contraception.2023.110136_bib13","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2023.110136_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15386\/mpr-1372","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu","year":"2020","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.contraception.2023.110136_bib15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.contraception.2016.05.014","article-title":"Combined hormonal contraceptive use among obese women and risk for cardiovascular events: a systematic review","volume":"94","author":"Horton","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib16","unstructured":"Faculty of Sexual and Reproductive Healthcare. UK medical eligibility criteria for contraceptive use. UKMEC 2016 (amended September 2019). \u3008https:\/\/www.fsrh.org\/documents\/ukmec-2016\/\u3009 (accessed June 2022)."},{"key":"10.1016\/j.contraception.2023.110136_bib17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00404-019-05340-4","article-title":"A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg","volume":"300","author":"Palacios","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.contraception.2023.110136_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","article-title":"Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability","volume":"92","author":"Archer","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib19","article-title":"A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24\/4-day regimen","volume":"2","author":"Kimble","year":"2020","journal-title":"Contracept X"},{"key":"10.1016\/j.contraception.2023.110136_bib20","unstructured":"Guideline on clinical investigation of steroid contraceptives in women. European Medicines Agency, 2005. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf\u3009 (accessed September 2022)."},{"key":"10.1016\/j.contraception.2023.110136_bib21","unstructured":"Establishing effectiveness and safety for hormal drug products indended to prevent pregnancy. Guidance for industry (draft). July 2019. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/establishing-effectiveness-and-safety-hormonal-drug-products-intended-prevent-pregnancy-guidance\u3009 (accessed September, 2022)."},{"key":"10.1016\/j.contraception.2023.110136_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2019.10.005","article-title":"Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females","volume":"101","author":"Richter","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib23","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2023.110136_bib24","unstructured":"World Health Organization. Medical eligibility criteria for contraceptive use. 2015. \u3008https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/181468\/9789241549158_eng.pdf\u3009 (accessed June 28, 2023)."},{"key":"10.1016\/j.contraception.2023.110136_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020952023","article-title":"Obesity, estrogens and adipose tissue dysfunction \u2013 implications for pulmonary arterial hypertension","volume":"10","author":"Mair","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.contraception.2023.110136_bib26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2010.04.016","article-title":"Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review","volume":"82","author":"Edelman","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.contraception.2019.01.003","article-title":"Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index","volume":"99","author":"Natavio","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.contraception.2016.03.006","article-title":"Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing","volume":"94","author":"Edelman","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-022-01960-2","article-title":"Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial","volume":"22","author":"Regidor","year":"2022","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.contraception.2023.110136_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.contraception.2022.07.009","article-title":"Pooled efficacy results of estetrol\/drospirenone combined oral contraception phase 3 trials","volume":"116","author":"Jensen","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110136_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2023.110136_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/13625187.2021.1957094","article-title":"Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 microg: a double-blind, double-dummy, prospective, randomised study","volume":"26","author":"Palacios","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2023.110136_bib33","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol ((Lausanne))"},{"key":"10.1016\/j.contraception.2023.110136_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423002305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423002305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:12:10Z","timestamp":1762117930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782423002305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"alternative-id":["S0010782423002305"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110136","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4\u00a0mg (24\/4-day regimen) in obese users","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110136"}}